Chitosan-Coated Silver–Vancomycin Nanoparticles for Treatment of Bacterial Endophthalmitis
Investigative Ophthalmology & Visual Science · 2026
DOI: 10.1167/iovs.67.3.20 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2026. Written by Henry Kolge and 4 co-authors. Institution: Department of Ophthalmology, Visual and Anatomical Sciences, Wayne State University School of Medicine, Detroit, Michigan, United States. Major MEDLINE topics: Endophthalmitis, Vancomycin, Chitosan, Silver. Cited 1 times so far (Crossref); 78 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Purpose
The rising incidence of drug-resistant ocular pathogens highlights the critical need for innovative therapeutic strategies. Here, we developed an antibacterial nanoformulation by combining silver with an antibiotic (vancomycin) and evaluated its efficacy using in vitro, ex vivo, and in vivo models of ocular Staphylococcus aureus infections.
Methods
Silver nanoparticles were synthesized through chemical reduction using silver nitrate and sodium citrate, subsequently loaded with vancomycin, and coated with chitosan to impart a positive surface charge. These nanoformulations were tested for their antimicrobial activity against S. aureus, including methicillin-resistant S. aureus (MRSA) and clinical isolates. The toxicity was evaluated in cultured human retinal Müller glia cells and mouse eyes. Ex vivo studies were performed using porcine/goat eyes and human vitreous. Therapeutic efficacy was evaluated in a mouse model of S. aureus endophthalmitis.
Results
Three formulations (AgNPs, CAgNPs, and CAgVNPs) ranged in size from 60 to 70 nm and demonstrated efficient vancomycin loading with controlled release in acidic conditions. Antimicrobial testing revealed synergistic antibacterial effects of nanoformulations against S. aureus, including MRSA and clinical isolates, resulting in a two- to fourfold reduction in minimum inhibitory concentration compared to vancomycin. Both in vitro and in vivo assays showed negligible cytotoxicity. All nanoformulations ameliorated the severity of S. aureus endophthalmitis, with CAgVNPs showing a marked reduction in bacterial burden (two- to sevenfold) and inflammatory cytokines (three- to fivefold). Moreover, CAgVNP-treated eyes exhibited reduced cell death and retinal tissue damage.
Conclusions
Our study demonstrates that the synergistic activity of chitosan-coated silver nanoparticles and antibiotics represents a promising therapeutic strategy for treating resistant ocular bacterial infections.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Ophthalmology, Visual and Anatomical Sciences, Wayne State University School of Medicine, Detroit, Michigan, United States.
- Department of Biochemistry, Microbiology, and Immunology, Wayne State University School of Medicine, Detroit, Michigan, United States.
Cite
APA
Kolge, H., Ahmad, Z., Singh, S., Yu, M., & Kumar, A. (2026). Chitosan-Coated Silver–Vancomycin Nanoparticles for Treatment of Bacterial Endophthalmitis. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.3.20
Vancouver
Kolge H, Ahmad Z, Singh S, Yu M, Kumar A. Chitosan-Coated Silver–Vancomycin Nanoparticles for Treatment of Bacterial Endophthalmitis. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.3.20
BibTeX
@article{Kolge2026,
author = {Kolge, Henry and Ahmad, Zeeshan and Singh, Sukhvinder and Yu, Michael and Kumar, Ashok},
title = {Chitosan-Coated Silver–Vancomycin Nanoparticles for Treatment of Bacterial Endophthalmitis},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
doi = {10.1167/iovs.67.3.20}
}
EUVIMED